Business Context and Reporting Period
Company: Neogen Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended November 30, 2007 (Fiscal Year 2008)
Business Overview: Neogen operates two reportable segments: Food Safety (diagnostic test kits for toxins, bacteria, and allergens) and Animal Safety (veterinary instruments, rodenticides, and consumables). The company completed a 3-for-2 stock split in August 2007.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Nov 30, 2007 | 6 Months Ended Nov 30, 2007 |
|---|---|---|
| Net Sales | $27,210 | $50,118 |
| Gross Margin | $14,171 (52.1%) | $26,468 (52.8%) |
| Operating Income | $4,798 (17.6%) | $9,345 (18.6%) |
| Net Income | $3,254 | $6,265 |
| Diluted EPS | $0.22 | $0.42 |
| Cash from Operations (6mo) | $2,259 | |
| Cash and Equivalents (Nov 30, 2007) | $10,415 | |
| Long-Term Debt | $0 (No amounts drawn on $10M line of credit) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 23% in the quarter and 18% year-to-date compared to the prior year periods.
- Segment Performance:
- Food Safety: Sales rose 23% (quarter) and 22% (YTD), driven by growth in Natural Toxins, Bacteria, and Dehydrated Culture Media. Neogen Europe sales increased over 40% in the quarter.
- Animal Safety: Sales rose 22% (quarter) and 14% (YTD). Growth was led by Veterinary Instruments (up 55% in the quarter), partially offset by declines in Life Sciences/Vaccines and Rodenticides due to mild weather.
- Acquisitions: The acquisition of Kane Enterprises Inc. in August 2007 contributed significantly to Animal Safety sales and inventory levels. A subsequent acquisition of Rivard Instruments Inc. occurred in December 2007.
- Margins: Gross margin percentage decreased slightly in the quarter (52.8% to 52.1%) due to the mix of acquired Kane sales but improved year-to-date (51.9% to 52.8%). Operating margins expanded in both periods due to economies of scale and cost controls.
Outlook, Risks, and Management Commentary
- Guidance: Management explicitly states it does not provide forecasts of future performance. Historical results may not be indicative of future performance.
- Liquidity: Management believes existing cash ($10.4M), the $10M undrawn credit facility, and future operating cash flows are sufficient for foreseeable needs. However, additional equity or financing may be required for future product commercialization or acquisitions.
- Market Risks:
- Foreign Exchange: Exposure to the British Pound and Euro; a weaker U.S. dollar increases reported sales value.
- Weather: Mild weather negatively impacted rodenticide sales.
- Competition & Regulation: Risks related to government regulation, patent protection, and competition.
- Accounting Updates: The company adopted FIN 48 (uncertainty in income taxes) with no significant effect. New standards SFAS 141(R) and SFAS 160 must be adopted by fiscal 2010; impact is expected to be minimal.
Investor Verification Checklist
- Acquisition Integration: Verify the synergistic fit and revenue contribution of the Kane Enterprises and Rivard Instruments acquisitions.
- Seasonality Impact: Assess the extent to which mild weather impacted rodenticide sales and if this is a recurring risk.
- European Growth: Confirm the sustainability of the >40% sales growth in Neogen Europe.
- Capital Allocation: Monitor the $1.25M share repurchase authorization (893k shares purchased to date) and future equity issuance needs.
- Intangible Assets: Review the $28.9M goodwill balance for potential impairment triggers given the aggressive acquisition strategy.